 Kristine Erlandson
Concepts (495)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 200 | 2026 | 3186 | 30.520 |
Why?
| | Frailty | 38 | 2026 | 203 | 13.940 |
Why?
| | Aging | 51 | 2026 | 1962 | 7.170 |
Why?
| | Sarcopenia | 13 | 2026 | 91 | 5.130 |
Why?
| | Exercise | 27 | 2026 | 2191 | 5.040 |
Why?
| | Anti-HIV Agents | 27 | 2026 | 908 | 4.210 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2026 | 442 | 4.040 |
Why?
| | HIV Integrase Inhibitors | 10 | 2026 | 79 | 3.910 |
Why?
| | Anti-Retroviral Agents | 16 | 2025 | 251 | 3.800 |
Why?
| | Antiretroviral Therapy, Highly Active | 15 | 2021 | 279 | 3.710 |
Why?
| | Middle Aged | 146 | 2026 | 36126 | 3.420 |
Why?
| | Exercise Therapy | 9 | 2026 | 475 | 3.300 |
Why?
| | Muscle, Skeletal | 14 | 2025 | 1789 | 3.260 |
Why?
| | Body Composition | 16 | 2026 | 690 | 3.250 |
Why?
| | Aged | 99 | 2026 | 26096 | 2.860 |
Why?
| | Accidental Falls | 12 | 2026 | 225 | 2.830 |
Why?
| | HIV-1 | 18 | 2024 | 906 | 2.830 |
Why?
| | Male | 169 | 2026 | 72664 | 2.760 |
Why?
| | Osteoporosis | 7 | 2025 | 237 | 2.740 |
Why?
| | Quinolines | 4 | 2026 | 190 | 2.630 |
Why?
| | Humans | 242 | 2026 | 145140 | 2.620 |
Why?
| | Inflammation | 20 | 2026 | 2876 | 2.590 |
Why?
| | Hand Strength | 9 | 2026 | 144 | 2.440 |
Why?
| | Cytomegalovirus Infections | 6 | 2026 | 206 | 2.380 |
Why?
| | Glucagon-Like Peptides | 3 | 2026 | 69 | 2.370 |
Why?
| | Acquired Immunodeficiency Syndrome | 6 | 2023 | 237 | 2.370 |
Why?
| | Female | 143 | 2026 | 78636 | 2.220 |
Why?
| | Walking Speed | 8 | 2025 | 53 | 2.220 |
Why?
| | Cardiovascular Diseases | 17 | 2026 | 2183 | 2.200 |
Why?
| | Weight Gain | 11 | 2026 | 561 | 2.130 |
Why?
| | Healthy Aging | 4 | 2025 | 44 | 2.070 |
Why?
| | Cohort Studies | 38 | 2026 | 5988 | 2.020 |
Why?
| | Adult | 101 | 2026 | 40665 | 2.000 |
Why?
| | Bone Density | 6 | 2025 | 484 | 1.870 |
Why?
| | Growth Hormone-Releasing Hormone | 4 | 2026 | 19 | 1.800 |
Why?
| | Adipose Tissue | 7 | 2020 | 644 | 1.790 |
Why?
| | Risk Factors | 40 | 2026 | 10857 | 1.650 |
Why?
| | High-Intensity Interval Training | 4 | 2026 | 45 | 1.530 |
Why?
| | Absorptiometry, Photon | 9 | 2026 | 276 | 1.510 |
Why?
| | Quality of Life | 16 | 2026 | 3194 | 1.470 |
Why?
| | Fatty Liver | 2 | 2025 | 253 | 1.400 |
Why?
| | Biomarkers | 19 | 2026 | 4282 | 1.400 |
Why?
| | HIV | 14 | 2023 | 251 | 1.390 |
Why?
| | Tenofovir | 6 | 2026 | 300 | 1.330 |
Why?
| | Lipopolysaccharide Receptors | 4 | 2022 | 88 | 1.280 |
Why?
| | Hospitalization | 7 | 2026 | 2458 | 1.210 |
Why?
| | Frail Elderly | 9 | 2026 | 136 | 1.190 |
Why?
| | Obesity, Abdominal | 2 | 2019 | 47 | 1.110 |
Why?
| | Pyridones | 3 | 2026 | 209 | 1.110 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 1092 | 1.110 |
Why?
| | Cross-Sectional Studies | 27 | 2025 | 5886 | 1.090 |
Why?
| | Disease Management | 5 | 2020 | 651 | 1.060 |
Why?
| | Comorbidity | 17 | 2024 | 1657 | 1.050 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 465 | 1.050 |
Why?
| | Activities of Daily Living | 5 | 2023 | 439 | 1.050 |
Why?
| | Rosuvastatin Calcium | 3 | 2015 | 21 | 1.030 |
Why?
| | Cognition | 6 | 2026 | 1262 | 1.010 |
Why?
| | Fractures, Bone | 4 | 2024 | 426 | 1.000 |
Why?
| | Muscles | 4 | 2024 | 330 | 0.980 |
Why?
| | Mass Screening | 2 | 2025 | 1354 | 0.970 |
Why?
| | Bone and Bones | 3 | 2026 | 317 | 0.960 |
Why?
| | Longitudinal Studies | 16 | 2026 | 2949 | 0.950 |
Why?
| | Prospective Studies | 24 | 2025 | 8035 | 0.930 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 61 | 0.930 |
Why?
| | Adiposity | 4 | 2019 | 532 | 0.910 |
Why?
| | Body Mass Index | 11 | 2026 | 2437 | 0.890 |
Why?
| | Psoas Muscles | 1 | 2025 | 14 | 0.880 |
Why?
| | Aged, 80 and over | 19 | 2026 | 8318 | 0.880 |
Why?
| | Self Efficacy | 4 | 2024 | 410 | 0.850 |
Why?
| | Metabolic Diseases | 2 | 2023 | 114 | 0.850 |
Why?
| | Alanine | 2 | 2026 | 168 | 0.830 |
Why?
| | DNA, Mitochondrial | 3 | 2021 | 211 | 0.830 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 766 | 0.830 |
Why?
| | Muscle Strength | 4 | 2022 | 332 | 0.830 |
Why?
| | Cytomegalovirus | 6 | 2026 | 168 | 0.800 |
Why?
| | HIV Long-Term Survivors | 2 | 2020 | 3 | 0.800 |
Why?
| | Advance Care Planning | 3 | 2021 | 244 | 0.800 |
Why?
| | Motor Activity | 4 | 2016 | 718 | 0.790 |
Why?
| | Cigarette Smoking | 1 | 2025 | 101 | 0.790 |
Why?
| | Physical Fitness | 2 | 2015 | 207 | 0.780 |
Why?
| | HIV Seropositivity | 5 | 2024 | 119 | 0.780 |
Why?
| | Neurocognitive Disorders | 3 | 2019 | 33 | 0.770 |
Why?
| | HIV Integrase | 1 | 2024 | 74 | 0.770 |
Why?
| | Telemedicine | 2 | 2023 | 956 | 0.760 |
Why?
| | CD4 Lymphocyte Count | 7 | 2020 | 280 | 0.750 |
Why?
| | Body Weight | 3 | 2016 | 969 | 0.740 |
Why?
| | Coronary Artery Disease | 3 | 2023 | 747 | 0.740 |
Why?
| | Advance Directives | 2 | 2021 | 88 | 0.710 |
Why?
| | Malnutrition | 1 | 2023 | 86 | 0.700 |
Why?
| | Telerehabilitation | 1 | 2022 | 46 | 0.690 |
Why?
| | Obesity | 6 | 2026 | 3097 | 0.690 |
Why?
| | Organ Transplantation | 1 | 2024 | 250 | 0.680 |
Why?
| | Double-Blind Method | 6 | 2026 | 2057 | 0.670 |
Why?
| | Lipodystrophy | 2 | 2023 | 12 | 0.670 |
Why?
| | Atazanavir Sulfate | 2 | 2020 | 42 | 0.660 |
Why?
| | United States | 23 | 2026 | 16065 | 0.650 |
Why?
| | Geriatric Assessment | 5 | 2026 | 238 | 0.650 |
Why?
| | Raltegravir Potassium | 1 | 2020 | 18 | 0.650 |
Why?
| | Guideline Adherence | 1 | 2025 | 586 | 0.650 |
Why?
| | Odds Ratio | 8 | 2022 | 1082 | 0.640 |
Why?
| | Darunavir | 1 | 2020 | 20 | 0.640 |
Why?
| | Heart Rate | 1 | 2024 | 855 | 0.640 |
Why?
| | Depression | 3 | 2025 | 1537 | 0.630 |
Why?
| | Hyperlipidemias | 1 | 2021 | 120 | 0.630 |
Why?
| | Vaccination Coverage | 2 | 2018 | 102 | 0.630 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 120 | 0.620 |
Why?
| | Metabolic Syndrome | 1 | 2024 | 360 | 0.620 |
Why?
| | Occupational Therapy | 1 | 2022 | 109 | 0.620 |
Why?
| | Prevalence | 13 | 2026 | 2855 | 0.610 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2024 | 265 | 0.610 |
Why?
| | Placebos | 5 | 2025 | 193 | 0.600 |
Why?
| | Mobile Applications | 1 | 2022 | 199 | 0.590 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 3 | 2019 | 9 | 0.590 |
Why?
| | Herpes Zoster Vaccine | 2 | 2018 | 154 | 0.590 |
Why?
| | Viral Load | 7 | 2024 | 525 | 0.580 |
Why?
| | Triazoles | 3 | 2026 | 187 | 0.580 |
Why?
| | Interleukin-10 | 1 | 2021 | 309 | 0.580 |
Why?
| | Haplotypes | 2 | 2020 | 498 | 0.570 |
Why?
| | Sex Factors | 5 | 2025 | 2099 | 0.560 |
Why?
| | Retrospective Studies | 18 | 2026 | 17247 | 0.550 |
Why?
| | Health Promotion | 1 | 2024 | 774 | 0.540 |
Why?
| | Herpes Zoster | 2 | 2018 | 318 | 0.530 |
Why?
| | Guidelines as Topic | 2 | 2019 | 266 | 0.530 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1131 | 0.520 |
Why?
| | Plague | 2 | 2015 | 60 | 0.520 |
Why?
| | Sexual and Gender Minorities | 2 | 2021 | 259 | 0.520 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 317 | 0.510 |
Why?
| | Lung | 4 | 2026 | 4101 | 0.510 |
Why?
| | Immunosenescence | 1 | 2017 | 5 | 0.510 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 115 | 0.500 |
Why?
| | Logistic Models | 6 | 2025 | 2133 | 0.500 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 310 | 0.490 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 24 | 0.480 |
Why?
| | Antibodies, Viral | 2 | 2024 | 673 | 0.480 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 229 | 0.480 |
Why?
| | Academic Medical Centers | 1 | 2019 | 552 | 0.480 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 3 | 0.480 |
Why?
| | Hormones | 1 | 2017 | 135 | 0.480 |
Why?
| | Yersinia pestis | 2 | 2015 | 45 | 0.460 |
Why?
| | Attitude to Health | 1 | 2019 | 429 | 0.460 |
Why?
| | Age Factors | 12 | 2026 | 3338 | 0.460 |
Why?
| | RNA, Viral | 3 | 2019 | 690 | 0.450 |
Why?
| | Muscular Atrophy | 1 | 2016 | 87 | 0.450 |
Why?
| | Integrases | 4 | 2024 | 122 | 0.440 |
Why?
| | Fluorobenzenes | 1 | 2015 | 17 | 0.440 |
Why?
| | Monocytes | 2 | 2015 | 537 | 0.440 |
Why?
| | Cannabis | 2 | 2023 | 509 | 0.430 |
Why?
| | Biomedical Research | 4 | 2024 | 717 | 0.430 |
Why?
| | Weight Loss | 4 | 2026 | 845 | 0.420 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 142 | 0.420 |
Why?
| | Plasma | 2 | 2018 | 223 | 0.420 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.420 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 12 | 0.420 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.410 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.410 |
Why?
| | Adipocytes | 1 | 2016 | 223 | 0.410 |
Why?
| | Pilot Projects | 5 | 2026 | 1889 | 0.410 |
Why?
| | Anticholesteremic Agents | 1 | 2015 | 155 | 0.400 |
Why?
| | Polypharmacy | 3 | 2024 | 94 | 0.400 |
Why?
| | Microbiota | 1 | 2021 | 729 | 0.400 |
Why?
| | Syphilis | 1 | 2014 | 38 | 0.390 |
Why?
| | Sarcoma, Kaposi | 1 | 2014 | 83 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2767 | 0.390 |
Why?
| | Motivation | 4 | 2024 | 600 | 0.390 |
Why?
| | Mycoses | 1 | 2014 | 88 | 0.390 |
Why?
| | Decision Making | 1 | 2021 | 974 | 0.390 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2014 | 130 | 0.380 |
Why?
| | Retinal Detachment | 1 | 2014 | 73 | 0.380 |
Why?
| | Self Report | 5 | 2022 | 867 | 0.380 |
Why?
| | Adenine | 2 | 2026 | 338 | 0.370 |
Why?
| | Incidence | 6 | 2026 | 2915 | 0.360 |
Why?
| | Transplant Recipients | 2 | 2024 | 180 | 0.360 |
Why?
| | Coinfection | 3 | 2021 | 143 | 0.360 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 190 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2026 | 1742 | 0.350 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.350 |
Why?
| | Proportional Hazards Models | 5 | 2026 | 1325 | 0.340 |
Why?
| | Pyrimidines | 1 | 2015 | 530 | 0.330 |
Why?
| | Pandemics | 4 | 2023 | 1703 | 0.330 |
Why?
| | Benzoxazines | 3 | 2023 | 31 | 0.330 |
Why?
| | Sulfonamides | 1 | 2015 | 583 | 0.320 |
Why?
| | Cyclopropanes | 3 | 2023 | 84 | 0.320 |
Why?
| | Lamivudine | 3 | 2017 | 65 | 0.320 |
Why?
| | Alkynes | 3 | 2023 | 67 | 0.320 |
Why?
| | Vitamin D | 1 | 2014 | 403 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.320 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1922 | 0.310 |
Why?
| | Mental Health | 3 | 2024 | 791 | 0.310 |
Why?
| | Metformin | 2 | 2024 | 327 | 0.310 |
Why?
| | Epigenesis, Genetic | 2 | 2026 | 672 | 0.310 |
Why?
| | Colorado | 7 | 2024 | 4538 | 0.300 |
Why?
| | Muscle Weakness | 2 | 2020 | 92 | 0.300 |
Why?
| | Survival Analysis | 4 | 2025 | 1371 | 0.300 |
Why?
| | Veterans | 4 | 2023 | 1625 | 0.290 |
Why?
| | Subcutaneous Fat | 5 | 2021 | 79 | 0.290 |
Why?
| | Case-Control Studies | 4 | 2019 | 3616 | 0.290 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 917 | 0.290 |
Why?
| | Disease Progression | 4 | 2024 | 2857 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2026 | 1138 | 0.280 |
Why?
| | Interleukin-6 | 3 | 2021 | 775 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 2 | 2021 | 80 | 0.270 |
Why?
| | Focus Groups | 3 | 2025 | 569 | 0.270 |
Why?
| | Virginiamycin | 1 | 2008 | 3 | 0.270 |
Why?
| | Emtricitabine | 2 | 2021 | 209 | 0.270 |
Why?
| | Vancomycin Resistance | 1 | 2008 | 16 | 0.270 |
Why?
| | Energy Metabolism | 1 | 2014 | 933 | 0.270 |
Why?
| | Immunoglobulin G | 3 | 2024 | 887 | 0.270 |
Why?
| | Oxazolidinones | 1 | 2008 | 17 | 0.270 |
Why?
| | Enterococcus | 1 | 2008 | 22 | 0.270 |
Why?
| | Canada | 4 | 2025 | 429 | 0.270 |
Why?
| | Treatment Outcome | 9 | 2026 | 11741 | 0.260 |
Why?
| | United Kingdom | 3 | 2025 | 336 | 0.260 |
Why?
| | Acetamides | 1 | 2008 | 39 | 0.260 |
Why?
| | Social Support | 2 | 2024 | 645 | 0.260 |
Why?
| | Surveys and Questionnaires | 10 | 2024 | 6055 | 0.260 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 410 | 0.260 |
Why?
| | Fatigue | 4 | 2026 | 363 | 0.250 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2008 | 71 | 0.250 |
Why?
| | Body Fat Distribution | 3 | 2019 | 46 | 0.250 |
Why?
| | Electronic Health Records | 2 | 2025 | 1188 | 0.250 |
Why?
| | Insulin Resistance | 1 | 2015 | 1244 | 0.250 |
Why?
| | Resistance Training | 2 | 2026 | 186 | 0.240 |
Why?
| | Anthropometry | 2 | 2017 | 205 | 0.240 |
Why?
| | Loneliness | 2 | 2024 | 63 | 0.240 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 919 | 0.230 |
Why?
| | Zidovudine | 2 | 2017 | 77 | 0.230 |
Why?
| | Radiography, Abdominal | 2 | 2017 | 44 | 0.220 |
Why?
| | Young Adult | 13 | 2025 | 14176 | 0.220 |
Why?
| | Bacteremia | 1 | 2008 | 222 | 0.220 |
Why?
| | Life Expectancy | 3 | 2020 | 73 | 0.220 |
Why?
| | Patient Dropouts | 1 | 2025 | 65 | 0.220 |
Why?
| | Independent Living | 3 | 2025 | 116 | 0.220 |
Why?
| | Risk Assessment | 6 | 2024 | 3740 | 0.220 |
Why?
| | Forced Expiratory Volume | 1 | 2026 | 450 | 0.220 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 58 | 0.210 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1393 | 0.210 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.210 |
Why?
| | Community Participation | 1 | 2025 | 123 | 0.210 |
Why?
| | Seroepidemiologic Studies | 1 | 2024 | 171 | 0.210 |
Why?
| | Thigh | 2 | 2022 | 48 | 0.210 |
Why?
| | Respiratory Function Tests | 1 | 2026 | 543 | 0.210 |
Why?
| | Substance Abuse, Intravenous | 1 | 2025 | 127 | 0.200 |
Why?
| | Methadone | 1 | 2025 | 122 | 0.200 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 168 | 0.200 |
Why?
| | Ireland | 4 | 2025 | 32 | 0.200 |
Why?
| | Blood Glucose | 1 | 2014 | 2335 | 0.200 |
Why?
| | Disability Evaluation | 3 | 2022 | 310 | 0.200 |
Why?
| | Qualitative Research | 5 | 2025 | 1671 | 0.200 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.200 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2025 | 148 | 0.200 |
Why?
| | Urinary Tract Infections | 1 | 2026 | 210 | 0.200 |
Why?
| | HIV Protease Inhibitors | 2 | 2021 | 69 | 0.190 |
Why?
| | Chronic Disease | 5 | 2023 | 1806 | 0.190 |
Why?
| | Cost of Illness | 1 | 2026 | 324 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3892 | 0.190 |
Why?
| | Prognosis | 3 | 2021 | 4310 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1043 | 0.190 |
Why?
| | Medication Adherence | 2 | 2018 | 540 | 0.190 |
Why?
| | Organizations | 1 | 2022 | 28 | 0.180 |
Why?
| | NF-kappa B | 1 | 2026 | 664 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2023 | 71 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 201 | 0.180 |
Why?
| | Computed Tomography Angiography | 1 | 2023 | 146 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 374 | 0.180 |
Why?
| | DNA Methylation | 2 | 2026 | 667 | 0.180 |
Why?
| | Homosexuality, Male | 2 | 2021 | 231 | 0.170 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 15 | 0.170 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 39 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2023 | 246 | 0.170 |
Why?
| | Coronary Angiography | 1 | 2023 | 328 | 0.170 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 57 | 0.170 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 1093 | 0.170 |
Why?
| | Counseling | 1 | 2024 | 400 | 0.170 |
Why?
| | Succinic Acid | 1 | 2021 | 46 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.170 |
Why?
| | Postural Balance | 1 | 2024 | 244 | 0.170 |
Why?
| | Isoniazid | 1 | 2021 | 70 | 0.170 |
Why?
| | North America | 1 | 2022 | 301 | 0.170 |
Why?
| | Immunity | 1 | 2022 | 140 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 247 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 437 | 0.170 |
Why?
| | Sequence Alignment | 1 | 2021 | 362 | 0.170 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 70 | 0.160 |
Why?
| | Italy | 1 | 2020 | 114 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | Epidemics | 1 | 2021 | 96 | 0.160 |
Why?
| | Program Evaluation | 1 | 2024 | 943 | 0.160 |
Why?
| | Feces | 2 | 2025 | 494 | 0.160 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 600 | 0.160 |
Why?
| | Hospitals, Teaching | 1 | 2020 | 120 | 0.160 |
Why?
| | Socioeconomic Factors | 2 | 2016 | 1321 | 0.150 |
Why?
| | Death | 1 | 2021 | 131 | 0.150 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 599 | 0.150 |
Why?
| | Actigraphy | 1 | 2020 | 147 | 0.150 |
Why?
| | Energy Intake | 1 | 2022 | 507 | 0.150 |
Why?
| | Self Care | 2 | 2021 | 388 | 0.150 |
Why?
| | Lipoproteins, LDL | 2 | 2022 | 119 | 0.150 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 307 | 0.150 |
Why?
| | Kidney Transplantation | 1 | 2026 | 710 | 0.150 |
Why?
| | Cause of Death | 2 | 2019 | 470 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2021 | 422 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 497 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 326 | 0.150 |
Why?
| | Blood Pressure | 1 | 2026 | 1778 | 0.140 |
Why?
| | Bone Diseases | 1 | 2019 | 61 | 0.140 |
Why?
| | Psychotropic Drugs | 1 | 2019 | 78 | 0.140 |
Why?
| | Waist Circumference | 1 | 2019 | 143 | 0.140 |
Why?
| | Lumbar Vertebrae | 2 | 2018 | 252 | 0.140 |
Why?
| | Survivors | 1 | 2022 | 522 | 0.140 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 60 | 0.140 |
Why?
| | Metagenome | 1 | 2019 | 126 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 217 | 0.130 |
Why?
| | Preventive Health Services | 1 | 2020 | 153 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1109 | 0.130 |
Why?
| | Femur Head | 1 | 2018 | 38 | 0.130 |
Why?
| | Zimbabwe | 2 | 2016 | 76 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2018 | 46 | 0.130 |
Why?
| | Metagenomics | 1 | 2019 | 149 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 552 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 560 | 0.130 |
Why?
| | Dysbiosis | 1 | 2019 | 187 | 0.130 |
Why?
| | Gait | 1 | 2020 | 312 | 0.130 |
Why?
| | Healthy Volunteers | 1 | 2018 | 219 | 0.130 |
Why?
| | Movement | 1 | 2019 | 293 | 0.130 |
Why?
| | Phenotype | 3 | 2026 | 3138 | 0.130 |
Why?
| | Dogs | 2 | 2015 | 438 | 0.130 |
Why?
| | Diagnostic Errors | 2 | 2015 | 178 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2024 | 836 | 0.120 |
Why?
| | Drug Discovery | 1 | 2018 | 153 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 267 | 0.120 |
Why?
| | Glucose | 1 | 2022 | 1048 | 0.120 |
Why?
| | Disease Susceptibility | 1 | 2018 | 343 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1216 | 0.120 |
Why?
| | Drug Combinations | 1 | 2017 | 396 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 946 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2022 | 862 | 0.110 |
Why?
| | Machine Learning | 1 | 2021 | 586 | 0.110 |
Why?
| | Attention | 1 | 2019 | 461 | 0.110 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.110 |
Why?
| | Disease Vectors | 1 | 2015 | 15 | 0.110 |
Why?
| | Adolescent | 7 | 2025 | 22479 | 0.110 |
Why?
| | Myalgia | 1 | 2015 | 13 | 0.110 |
Why?
| | Pseudomonas | 1 | 2015 | 30 | 0.110 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 44 | 0.110 |
Why?
| | Diet | 2 | 2022 | 1277 | 0.110 |
Why?
| | Puerto Rico | 2 | 2025 | 61 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 872 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2115 | 0.110 |
Why?
| | Dog Diseases | 1 | 2015 | 70 | 0.100 |
Why?
| | Dideoxynucleosides | 1 | 2014 | 24 | 0.100 |
Why?
| | Microbiological Techniques | 1 | 2014 | 30 | 0.100 |
Why?
| | Genetic Markers | 1 | 2015 | 333 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 477 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1134 | 0.100 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 38 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 113 | 0.100 |
Why?
| | Computational Biology | 1 | 2019 | 669 | 0.100 |
Why?
| | Herpesvirus 8, Human | 1 | 2014 | 67 | 0.100 |
Why?
| | Fever | 1 | 2015 | 318 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 16 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 967 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 250 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 150 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2016 | 320 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2026 | 2961 | 0.100 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.100 |
Why?
| | Lopinavir | 1 | 2013 | 30 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 847 | 0.090 |
Why?
| | Radiography | 1 | 2015 | 852 | 0.090 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 100 | 0.090 |
Why?
| | Neoplasms | 2 | 2019 | 2900 | 0.090 |
Why?
| | Regression Analysis | 1 | 2015 | 998 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 425 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 767 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.090 |
Why?
| | Oligopeptides | 1 | 2013 | 266 | 0.080 |
Why?
| | Outpatients | 1 | 2014 | 447 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1506 | 0.080 |
Why?
| | Visual Acuity | 1 | 2014 | 491 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5411 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1955 | 0.080 |
Why?
| | Pregnancy | 1 | 2023 | 7182 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 499 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1154 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2578 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1099 | 0.070 |
Why?
| | Research Design | 2 | 2025 | 1132 | 0.070 |
Why?
| | Pyridines | 1 | 2013 | 608 | 0.070 |
Why?
| | Interviews as Topic | 2 | 2024 | 907 | 0.070 |
Why?
| | Linezolid | 1 | 2008 | 25 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2019 | 223 | 0.070 |
Why?
| | Animals | 3 | 2021 | 37952 | 0.060 |
Why?
| | Baltimore | 1 | 2025 | 72 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2026 | 123 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3410 | 0.050 |
Why?
| | Missouri | 1 | 2024 | 66 | 0.050 |
Why?
| | Bias | 1 | 2025 | 197 | 0.050 |
Why?
| | Mortality | 2 | 2019 | 378 | 0.050 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2023 | 9 | 0.050 |
Why?
| | Registries | 2 | 2024 | 2401 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 368 | 0.050 |
Why?
| | Ohio | 1 | 2023 | 146 | 0.050 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.050 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 186 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 573 | 0.050 |
Why?
| | Intention | 1 | 2024 | 186 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 507 | 0.050 |
Why?
| | Nucleosides | 1 | 2022 | 25 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 147 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2022 | 24 | 0.050 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2022 | 87 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2023 | 174 | 0.050 |
Why?
| | Cocaine | 1 | 2024 | 161 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2023 | 133 | 0.040 |
Why?
| | Faculty | 1 | 2023 | 147 | 0.040 |
Why?
| | Concept Formation | 1 | 2022 | 32 | 0.040 |
Why?
| | Habits | 1 | 2022 | 52 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 222 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 261 | 0.040 |
Why?
| | Citric Acid | 1 | 2021 | 33 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 79 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2024 | 373 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2022 | 193 | 0.040 |
Why?
| | Mentors | 1 | 2023 | 216 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1002 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2026 | 0.040 |
Why?
| | New York City | 1 | 2020 | 84 | 0.040 |
Why?
| | Heart Failure | 1 | 2014 | 2324 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 101 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1134 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 325 | 0.040 |
Why?
| | Europe | 1 | 2021 | 416 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 67 | 0.040 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2019 | 15 | 0.040 |
Why?
| | Marijuana Use | 1 | 2023 | 221 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 99 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 781 | 0.040 |
Why?
| | Antitubercular Agents | 1 | 2021 | 208 | 0.040 |
Why?
| | Cardiorespiratory Fitness | 1 | 2020 | 74 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 765 | 0.040 |
Why?
| | Hip Fractures | 1 | 2020 | 87 | 0.040 |
Why?
| | Health Behavior | 1 | 2024 | 787 | 0.040 |
Why?
| | Demography | 1 | 2019 | 282 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 167 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.030 |
Why?
| | Geriatrics | 1 | 2019 | 95 | 0.030 |
Why?
| | AIDS-Associated Nephropathy | 1 | 2018 | 7 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 478 | 0.030 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 20 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 459 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2018 | 52 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2023 | 1038 | 0.030 |
Why?
| | Models, Statistical | 1 | 2022 | 671 | 0.030 |
Why?
| | Psychometrics | 1 | 2022 | 731 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2019 | 224 | 0.030 |
Why?
| | Hair | 1 | 2018 | 84 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2023 | 775 | 0.030 |
Why?
| | RNA | 1 | 2023 | 910 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 881 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3918 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 60 | 0.030 |
Why?
| | Haiti | 1 | 2016 | 14 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 19 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 899 | 0.030 |
Why?
| | Menopause | 1 | 2019 | 326 | 0.030 |
Why?
| | Research | 1 | 2019 | 430 | 0.030 |
Why?
| | Peru | 1 | 2016 | 60 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 57 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1079 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 513 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 423 | 0.030 |
Why?
| | Brazil | 1 | 2016 | 179 | 0.030 |
Why?
| | India | 1 | 2016 | 213 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 571 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1145 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7107 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 266 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1546 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.030 |
Why?
| | Wisconsin | 1 | 2014 | 99 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 832 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2016 | 134 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2017 | 529 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2015 | 419 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 404 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4071 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1269 | 0.020 |
Why?
| | Brain | 1 | 2021 | 2934 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 1494 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1893 | 0.010 |
Why?
|
|
Erlandson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|